Wegovy vs Zepbound: What the Latest Research Actually Says About Which Works Better

When two of the most powerful weight loss medications ever developed go head-to-head, the results are hard to ignore. A landmark 2024 cohort study published in JAMA Internal Medicine analyzed over 41,000 adults with overweight or obesity and found that tirzepatide users were 3.24 times more likely to achieve 15% or greater weight loss compared to semaglutide users. That is not a marginal difference. That is a clinically meaningful gap that has real implications for anyone weighing these two options.

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both weekly injectable medications approved specifically for chronic weight management. They share a similar mechanism at the surface level — both activate GLP-1 receptors in the gut and brain to reduce appetite, slow gastric emptying, and improve insulin sensitivity. But underneath that similarity lies a fundamental biochemical distinction that appears to translate directly into different outcomes on the scale and in the mirror.

The Science Behind the Difference

Semaglutide is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which your gut naturally releases after eating. Tirzepatide, the active ingredient in Zepbound, goes one step further. It is a dual GIP/GLP-1 receptor co-agonist, meaning it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously. As Nauck and D’Alessio explained in a 2022 review in Cardiovascular Diabetology, both receptors are expressed not just in the pancreas but in regions of the brain that regulate food intake — and activating both appears to create a synergistic appetite-suppressing effect that neither receptor alone can fully replicate.

This dual mechanism is likely why the numbers look the way they do. In the same JAMA Internal Medicine cohort study, patients on tirzepatide lost an average of 6.9 percentage points more body weight at 12 months than those on semaglutide. At six months, the difference was already 4.3%. These are not rounding errors. For a 220-pound man, a 6.9% additional weight reduction translates to roughly 15 extra pounds over the course of a year. A 2024 systematic review and network meta-analysis published in Diabetologia reinforced this, finding that tirzepatide 15 mg was the most efficacious treatment across both HbA1c reduction and body weight reduction when compared against semaglutide across all doses in adults with type 2 diabetes.

A broad 2025 systematic review in the Annals of Internal Medicine examined 26 randomized controlled trials covering over 15,000 participants without diabetes and confirmed that GLP-1 receptor agonists and co-agonists like tirzepatide are genuinely efficacious for weight loss, with gastrointestinal side effects being the primary safety concern. Importantly, the JAMA Internal Medicine cohort study found that rates of gastrointestinal adverse events — nausea, vomiting, diarrhea — were similar between tirzepatide and semaglutide users. So the advantage in weight loss does not appear to come at the cost of worse tolerability.

Where Semaglutide Holds Its Own

It would be a mistake to dismiss Wegovy based on the weight loss comparison alone. Semaglutide has a substantially longer track record, a larger body of cardiovascular outcome data, and arguably more real-world experience at the population level. The STEP trials established semaglutide’s efficacy years before tirzepatide entered the obesity treatment space, and the cardiovascular benefits of semaglutide — particularly in the SELECT trial — are well-documented in patients with established heart disease.

When it comes to heart failure specifically, the picture gets nuanced. A 2025 study published in JAMA examined outcomes in patients with heart failure with preserved ejection fraction — a condition strongly linked to obesity and metabolic dysfunction — and found that both semaglutide and tirzepatide reduced the composite risk of heart failure hospitalization or all-cause mortality by more than 40% compared to a placebo proxy, but tirzepatide showed no meaningful additional benefit over semaglutide in this specific population. The hazard ratio for tirzepatide versus semaglutide in that head-to-head analysis was 0.86 — directionally favoring tirzepatide, but not statistically significant. What this tells you is that in cardiometabolic heart failure, both drugs are working hard, and the gap between them closes when the outcome is survival rather than pounds lost.

For men who are primarily focused on fat loss, metabolic health improvement, or body composition — and who do not have active heart failure — the weight loss superiority of tirzepatide is the more relevant data point. For men with complex cardiovascular histories, the conversation belongs in a cardiologist’s office, where both options deserve serious consideration.

Cost and access remain real-world variables that no study can fully account for. Zepbound is newer, and depending on your insurance situation and pharmacy, the out-of-pocket costs can differ significantly. Manufacturer savings programs exist for both drugs, but coverage remains inconsistent across employers and states. This practical reality means that for some men, Wegovy is simply the more accessible option — and a highly effective one at that. Losing 12–15% of body weight on semaglutide, which many clinical trial participants achieved, is still a transformative outcome.

What This Means If You’re Deciding Between Them

If maximum weight loss is your primary objective and you have no significant contraindications, the current evidence favors tirzepatide. The real-world data from over 18,000 propensity-matched patients, the network meta-analysis data, and the mechanistic rationale all point in the same direction. Starting doses for Zepbound are 2.5 mg weekly, titrating up to a target dose of 5 mg, 10 mg, or 15 mg over several months — with higher doses consistently producing greater weight reduction in clinical trials.

If you are already on Wegovy and tolerating it well, that does not automatically mean you should switch. Response to these medications is individual, and some men do exceptionally well on semaglutide. If you have plateaued and are not achieving the results you are looking for, that is a legitimate reason to discuss tirzepatide with your prescriber. If you are cardiovascular-risk-focused, both drugs are showing strong signals for benefit, and your cardiologist’s input matters more than a headline.

It is also worth stating plainly: neither medication replaces the fundamentals. Resistance training during any GLP-1 medication course is not optional — it is essential for preserving lean muscle mass as weight drops. Protein intake needs to stay high, sleep needs to stay consistent, and the behaviors that govern long-term metabolic health do not take a vacation just because a medication is suppressing your appetite. These drugs work best when they are amplifying a lifestyle that is already pointed in the right direction.

The Takeaway

Wegovy and Zepbound are both legitimate, science-backed tools for men who need meaningful pharmacological support for weight loss. But the data is increasingly clear that tirzepatide produces greater weight reduction — roughly 7% more at one year in real-world comparisons — without a corresponding increase in side effects. For heart failure outcomes, both drugs appear comparably protective. The decision ultimately comes down to your individual health profile, your prescriber’s recommendation, and what you can actually access and afford. What should not factor into that decision is marketing. Let the evidence lead.